Great Lakes Advisors LLC Makes New $15.82 Million Investment in Masimo Co. (NASDAQ:MASI)

Great Lakes Advisors LLC bought a new position in shares of Masimo Co. (NASDAQ:MASI) during the fourth quarter, HoldingsChannel.com reports. The firm bought 95,730 shares of the medical equipment provider’s stock, valued at approximately $15,824,000.

Several other institutional investors and hedge funds have also recently modified their holdings of MASI. Jones Financial Companies Lllp bought a new stake in shares of Masimo during the fourth quarter valued at approximately $27,000. UMB Bank n.a. raised its position in shares of Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new stake in shares of Masimo during the fourth quarter valued at approximately $33,000. Blue Trust Inc. raised its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Wells Fargo & Company raised their target price on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Piper Sandler raised their target price on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and an average price target of $194.80.

Insiders Place Their Bets

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.70% of the stock is owned by insiders.

Masimo Stock Up 0.7 %

NASDAQ MASI opened at $167.67 on Thursday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average of $174.96 and a two-hundred day moving average of $156.95. The firm has a market capitalization of $9.05 billion, a price-to-earnings ratio of 115.63 and a beta of 1.03. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.